valuation efficiency of modern antidepressants by means of quantative pharmaco-EEG
Аннотация
Introduction. Currently, topicality the problem of diagnosis and treatment of depressive disorders (DD) in medical practice is not in doubt. The drugs of choice in the treatment of this affective disease are the selective serotonin reuptake inhibitors (SSRIs). One of the best known and widely used today of representatives a number of SSRIs is fluoxetine. An example perspective way to improve the pharmacotherapy of depression is to combine SSIRs with representatives of other groups of drugs. Great interest from this point of view is the hormone of pineal gland - melatonin (MT), which is an important element of the non-specific antistress system of body. One more potentially significant vector of perfecting therapy is searching/development of the new, more potent and fast-acting antidepressants. In this respect, the attention of researchers attracts agonist to MT1- and MT2-receptors and antagonist to 5-HT2C-receptors - valdoxan. Materials and methods. In this study, by means of quantitative pharmaco-EEG (QPEEG) was performed a comparative evaluation of pharmacological activity of valdoxan, fluoxetine and combination of fluoxetine with melaxen during rat's experimental depression (ED) and depressive disorder (DD) in patients. Pharmacoeconomic analysis was performed by the method of "cost/effectiveness". Results and discussion. It was established that reception of valdoxan and combined fluoxetine with melaxen promotes a more rapid normalization of bioelectric activity of brain than at fluoxetine usage separately. So, on the EEG at rats with ED was registered significant increase of theta-rhythm activity, which dominates in the norm, and at patients with DD this regime of pharmacotherapy normalized the distribution of the alpha-rhythm and reduced slow-wave activity. Conclusions. Evaluation efficiency of the above regimes of pharmacotherapy of depressive frustration showed, that the application of valdoxan, and also combination fluoxetine+melaxen favorably affects the course of the disease and contributes to a more rapid normalization of bioelectric activity of brain than fluoxetine in isolation, both experimentally and clinically.